Lexaria Bioscience Corp. (LEXX) AI Stock Analysis
LEXX AI stock analysis summary
AI ResearchLexaria Bioscience Corp. is a biotechnology company developing drug delivery technologies, led by its proprietary DehydraTECH platform. In FY2025, revenue grew 52.0% to $705,923, though net losses widened to -$11.9M. As of May 31, 2026, the company held $3.6M in cash and short-term investments with minimal debt of $86,714.
- Market cap
- $6.0M
- Revenue (TTM)
- $194,000
- P/E
- —
- 1Y return
- -76.9% S&P 500 16.8%
- Avg. target
- $82.50 2784.6% vs last close
Bull case
- FY2025 revenue grew 52.0% to $705,923, accompanied by a gross margin of 99.6%.
- The company maintains a liquid balance sheet with $3.6M in cash and short-term investments and net cash of $3.5M as of May 31, 2026.
- The mean analyst price target of $82.50 suggests a 2784.6% increase relative to the last closing price of $2.86.
Bear case
- The company reported a widening net loss of -$11.9M and negative free cash flow of -$10.5M in FY2025.
- In the latest quarter ended May 31, 2026, revenue dropped 88.5% year-over-year, bringing trailing twelve months revenue to $194,000.
- Shareholder dilution has been substantial, with the 5-year share count expanding by 333.1%.
What Lexaria Bioscience does
Lexaria Bioscience Corp. operates in two segments: Intellectual Property Licensing and B2B Production. At the core of its portfolio is DehydraTECH, a proprietary technology designed to enhance the delivery, bioavailability, and ingestion methods of bioactive compounds, while reducing required dosing. DehydraTECH is applied across fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, nicotine and its analogs, and cannabinoids, and can facilitate drug delivery across the blood-brain barrier. Founded in 2004 and based in Kelowna, Canada, the company operates a licensed in-house laboratory with 27 granted patents and approximately 50 patents pending worldwide.
Growth and profitability
Lexaria's revenue grew at a 5-year CAGR of 12.9% between FY2020 and FY2025. Annual revenue reached $705,923 in FY2025, up 52.0% from $464,278 in FY2024, supported by a 99.6% gross margin. However, operating expenses and an R&D outlay of $8.2M drove net losses from -$5.8M in FY2024 to -$11.9M in FY2025, resulting in an operating margin of -1683.0%. For the trailing twelve months ended May 31, 2026, revenue stood at $194,000 with an operating margin of -3862.9%. In the latest quarter ended May 31, 2026, quarterly revenue fell 88.5% year-over-year.
Balance sheet and cash flow
As of May 31, 2026, Lexaria held $3.6M in cash and short-term investments against total debt of $86,714, resulting in net cash of $3.5M. The current ratio stood at 10.60 and debt-to-equity was 0.02. In FY2025, the company used -$10.5M in free cash flow, with capital expenditures of $24,643. To support operations and research, the share count increased by 333.1% over a 5-year period.
Valuation and performance
LEXX trades at a price-to-sales multiple of 31.1x and an EV-to-revenue multiple of 16.9x, both significantly above the median of its US-listed Healthcare peers, which carries a price-to-sales median of 4.1x. The company's price-to-book ratio is 1.4x, with a market capitalization of $6.0M. Over the past year, LEXX shares declined 76.9%, underperforming the S&P 500's gain of 16.8%. Over a 5-year span, the stock fell 97.2%, compared to an 83.0% return for the S&P 500.
What analysts expect
One analyst covers Lexaria Bioscience Corp. for the next fiscal year, projecting FY2027 revenue of $1.4M and an EPS of -$4.65. For the current fiscal year ending August 31, 2026, consensus estimates anticipate revenue of $20,000 and an EPS of -$4.05. The mean analyst price target is $82.50, representing an upside of 2784.6% from the last closing price of $2.86. The company beat EPS expectations in 3 of the last 4 quarters, with its next earnings report scheduled for November 25, 2026.
Key risks and what to watch
- Ongoing cash burn is significant, with negative operating cash flow reaching -$10.5M in FY2025 against $3.6M in cash as of May 31, 2026.
- The stock has experienced severe downside momentum, dropping 76.9% over the past year and trading 69.4% below its 200-day average.
- Lexaria's price-to-sales multiple of 31.1x is elevated relative to the US-listed Healthcare peer median of 4.1x.
- Short interest is elevated, with short percent of float standing at 13.4%.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this LEXX AI stock analysis
This page is an AI-written research summary of Lexaria Bioscience Corp. (LEXX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: LEXX income statement, LEXX balance sheet, LEXX key metrics, LEXX analyst forecast, LEXX chart. See the LEXX stock overview for the latest quote and news.
LEXX AI stock analysis FAQ
What is Lexaria Bioscience's primary technology?
Lexaria develops DehydraTECH, a proprietary drug delivery platform that enhances bioavailability and ingestion across various active molecules, supported by 27 granted patents and approximately 50 pending patents worldwide.
How did Lexaria perform financially in FY2025?
In FY2025, revenue increased 52.0% to $705,923 with a 99.6% gross margin, but high R&D spending of $8.2M contributed to a net loss of -$11.9M.
What does Lexaria's balance sheet look like?
As of May 31, 2026, Lexaria held $3.6M in cash and short-term investments, total debt of $86,714, and had a current ratio of 10.60.
When is Lexaria's next earnings report?
Lexaria is scheduled to report its next earnings on November 25, 2026.